黏菌素相关急性肾损伤的归因风险与时间进程
该回顾性队列研究通过倾向性评分匹配,比较了黏菌素暴露患者与使用其他广谱抗生素的对照患者。结果显示黏菌素组急性肾损伤发生率为51%,对照组为22%,风险差29%,且在暴露72小时内即出现早期肾毒性。
要点
- 黏菌素暴露患者急性肾损伤风险显著高于匹配对照,风险差29%。
- 肾毒性在治疗72小时内即可出现,需早期监测肾功能。
- 基线血红蛋白浓度影响黏菌素肾毒性的效应。
核心结论
- 黏菌素与大量超额急性肾损伤相关,且在治疗最初72小时内即显现。
- 黏菌素的毒性效应随基线血红蛋白浓度而变化。
研究设计与样本
- 回顾性队列研究,纳入因多重耐药假单胞菌、克雷伯菌或不动杆菌属感染治疗的患者。
- 采用倾向性评分匹配黏菌素暴露组与未暴露对照组,共150对匹配配对。
- 急性肾损伤依据KDIGO肌酐标准定义。
主要发现
- 黏菌素组急性肾损伤发生率为77/150(51%),匹配对照组为33/150(22%)。
- 风险差为29%(95%CI 19至39),对应需伤害人数为3.5。
- 暴露72小时时黏菌素组急性肾损伤风险更高,发生率比为1.9(95%CI 1.1至3.5)。
- 两组中发生急性肾损伤的患者,若住院期间肾功能恢复至基线,则院内死亡率较低。
- 黏菌素暴露对急性肾损伤风险的影响随基线血红蛋白浓度呈反向变化。
临床怎么用
- 使用黏菌素治疗多重耐药革兰阴性菌感染时,应在最初72小时内密切监测肾功能。
- 基线血红蛋白浓度可能有助于识别黏菌素肾毒性高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Despite colistin's longstanding reported association with nephrotoxicity, the attributable risk and timing of toxicity onset are still unknown. Whether substantial toxicity occurs during the initial 72 hours of exposure has important implications for early treatment decisions. The objective of this study was to compare colistin-exposed patients with a matched control group given other broad spectrum antibiotics. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study in patients treated for multidrug-resistant Pseudomonas, Klebsiella, or Acinetobacter spp. Colistin-exposed patients were matched to unexposed controls using propensity scores. AKI was defined according to the Kidney Disease Improving Global Outcomes creatinine criteria. Incidence rate ratios and risk differences of AKI in the matched cohort were estimated with the generalized estimating equation Poisson regression model. Risk factors for AKI were tested for effect modification in the matched cohort. RESULTS: The study included 150 propensity-matched pairs with similar types of infection, similar delays to effective treatment, and similar baseline characteristics. Incidence of AKI was 77 of 150 (51%) in the colistin group versus 33 of 150 (22%) in matched controls (risk difference, 29%; 95% confidence interval, 19 to 39), corresponding to a number needed to harm of 3.5. Early toxicity was apparent, because AKI risk was higher in colistin-exposed patients at 72 hours of exposure (incidence rate ratio, 1.9; 95% confidence interval, 1.1 to 3.5). In both groups, hospital mortality in patients who experienced AKI was lower if kidney function returned to baseline during hospitalization. The effect of colistin exposure on AKI risk varied inversely according to baseline hemoglobin concentration. CONCLUSIONS: Colistin is associated with substantial excess AKI that is apparent within the first 72 hours of treatment. Colistin's toxicity varied according to baseline hemoglobin concentration. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_03_15_CJASNPodcast_18_4_M.mp3.
引用
- Miano TA, Lautenbach E, Wilson FP, et al. Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury. Clin J Am Soc Nephrol. 2018. PMID: 29545383. doi:10.2215/CJN.06980717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。